Takahara, Mitsuyoshi
Mita, Tomoya
Katakami, Naoto
Wada, Fumitaka
Morita, Naru
Kidani, Yoko
Yajima, Toshitaka
Shimomura, Iichiro
Watada, Hirotaka
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER
https://doi.org/10.1007/s13300-021-01192-x
Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
https://doi.org/10.1136/bmjdrc-2020-001585
Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol
https://doi.org/10.1007/s13300-017-0351-7
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
https://doi.org/10.1186/s12933-018-0787-8
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
https://doi.org/10.1136/bmjopen-2019-034613
Funding for this research was provided by:
AstraZeneca K.K.
Ono Pharmaceutical
Article History
Received: 4 November 2021
Accepted: 8 December 2021
First Online: 28 December 2021